Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma

Sang Min Yoon, Young-Suk Lim, Mee Jin Park, So Yeon Kim, Byungchul Cho, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Sung Gyu Lee, Yu Sun Lee, Jin-Hong Park, Jong Hoon Kim, Sang Min Yoon, Young-Suk Lim, Mee Jin Park, So Yeon Kim, Byungchul Cho, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Sung Gyu Lee, Yu Sun Lee, Jin-Hong Park, Jong Hoon Kim

Abstract

Background: Even with early stage hepatocellular carcinoma (HCC), patients are often ineligible for surgical resection, transplantation, or local ablation due to advanced cirrhosis, donor shortage, or difficult location. Stereotactic body radiation therapy (SBRT) has been established as a standard treatment option for patients with stage I lung cancer, who are not eligible for surgery, and may be a promising alternative treatment for patients with small HCC who are not eligible for curative treatment.

Materials and methods: A registry database of 93 patients who were treated with SBRT for HCC between 2007 and 2009 was analyzed. A dose of 10-20 Gy per fraction was given over 3-4 consecutive days, resulting in a total dose of 30-60 Gy. The tumor response was determined using dynamic computed tomography or magnetic resonance imaging, which was performed 3 months after completion of SBRT.

Results: The median follow-up period was 25.6 months. Median size of tumors was 2 cm (range: 1-6 cm). Overall patients' survival rates at 1 and 3 years were 86.0% and 53.8%, respectively. Complete and partial tumor response were achieved in 15.5% and 45.7% of patients, respectively. Local recurrence-free survival rate was 92.1% at 3 years. Most local failures were found in patients with HCCs > 3 cm, and local control rate at 3 years was 76.3% in patients with HCC > 3 cm, 93.3% in patients with tumors between 2.1-3 cm, and 100% in patients with tumors ≤ 2 cm, respectively. Out-of-field intrahepatic recurrence-free survival rates at 1 and 3 years were 51.9% and 32.4%, respectively. Grade ≥ 3 hepatic toxicity was observed in 6 (6.5%).

Conclusions: SBRT was effective in local control of small HCC. SBRT may be a promising alternative treatment for patients with small HCC which is unsuitable for other curative therapy.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow diagram of this study.
Figure 1. Flow diagram of this study.
Figure 2. Overall survival rates of the…
Figure 2. Overall survival rates of the enrolled patients.
The 1 and 3 years survival rates are 86.0% and 53.8%, respectively.
Figure 3. Local control and recurrence-free survival…
Figure 3. Local control and recurrence-free survival rates.
(A) The local control rates at 1 and 3 years were 94.8% and 92.1%, respectively. (B) Distant metastasis-free survival rates and (C) Intrahepatic recurrence-free survival rates following SBRT.
Figure 4. Analysis of local failures.
Figure 4. Analysis of local failures.
Most local failures occurred in patients with HCCs > 3 cm, and the local control rate at 3 years was 76.3% in these cases, 93.3% in patients with HCCs between 2.1-3 cm, and 100% in patients with HCCs

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi:10.1002/ijc.25516. PubMed: .
    1. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022. doi:10.1002/hep.24199. PubMed: .
    1. Lau WY, Lai EC (2007) Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. Ann Surg Oncol 14: 3301-3309. doi:10.1245/s10434-007-9549-7. PubMed: .
    1. Krishnan S, Dawson LA, Seong J, Akine Y, Beddar S et al. (2008) Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol 15: 1015-1024. doi:10.1245/s10434-007-9729-5. PubMed: .
    1. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ et al. (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81: e447-e453. doi:10.1016/j.ijrobp.2011.04.011. PubMed: .
    1. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS et al. (2010) Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10: 475. doi:10.1186/1471-2407-10-475. PubMed: .
    1. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ et al. (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 45: 831-837. doi:10.1080/02841860600897934. PubMed: .
    1. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B et al. (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26: 657-664. doi:10.1200/JCO.2007.14.3529. PubMed: .
    1. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A et al. (2005) A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62: 1371-1378. doi:10.1016/j.ijrobp.2005.01.002. PubMed: .
    1. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK et al. (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76: S94-100. doi:10.1016/j.ijrobp.2009.06.092. PubMed: .
    1. Ishii H, Furuse J, Kinoshita T, Konishi M, Nakagohri T et al. (2008) Hepatectomy for hepatocellular carcinoma patients who meet the Milan criteria. Hepatogastroenterology 55: 621-626. PubMed: .
    1. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH et al. (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243: 321-328. doi:10.1097/01.sla.0000201480.65519.b8. PubMed: .
    1. Feng K, Yan J, Li X, Xia F, Ma K et al. (2012) A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 57: 794-802. doi:10.1016/j.jhep.2012.05.007. PubMed: .
    1. Huang J, Yan L, Cheng Z, Wu H, Du L et al. (2010) A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 252: 903-912. doi:10.1097/SLA.0b013e3181efc656. PubMed: .
    1. Lencioni R (2010) Loco-regional treatment of hepatocellular carcinoma. Hepatology 52: 762-773. doi:10.1002/hep.23725. PubMed: .
    1. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255. doi:10.1016/S0140-6736(11)61347-0. PubMed: .
    1. Huang WY, Jen YM, Lee MS, Chang LP, Chen CM et al. (2012) Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 84: 355-361. doi:10.1016/j.ijrobp.2011.11.058. PubMed: .
    1. Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW et al. (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102: 209-214. doi:10.1002/jso.21593. PubMed: .
    1. Taguchi H, Sakuhara Y, Hige S, Kitamura K, Osaka Y et al. (2007) Intercepting radiotherapy using a real-time tumor-tracking radiotherapy system for highly selected patients with hepatocellular carcinoma unresec table with other modalities. Int J Radiat Oncol Biol Phys 69: 376-380. doi:10.1016/j.ijrobp.2007.07.1483. PubMed: .
    1. Livraghi T, Lazzaroni S, Meloni F (2001) Radiofrequency thermal ablation of hepatocellular carcinoma. Eur J Ultrasound 13: 159-166. doi:10.1016/S0929-8266(01)00128-8. PubMed: .
    1. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M et al. (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40: 1352-1360. doi:10.1002/hep.20465. PubMed: .
    1. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO et al. (2005) Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11: 1086-1092. doi:10.1002/lt.20472. PubMed: .
    1. Yang W, Chen MH, Yin SS, Yan K, Gao W et al. (2006) Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence. AJR Am J Roentgenol 186: S275-S283. doi:10.2214/AJR.04.1573. PubMed: .
    1. Bae SH, Park HC, Lim do H, Lee JA, Gwak GY et al. (2012) Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 82: e603-e607. doi:10.1016/j.ijrobp.2011.09.053. PubMed: .
    1. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P et al. (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 12: 218-225. doi:10.1007/s12094-010-0492-x. PubMed: .

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel